首页> 外文期刊>Journal of Medicinal Chemistry >Discovery of Multitarget Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator for Associated Pulmonary Diseases
【24h】

Discovery of Multitarget Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator for Associated Pulmonary Diseases

机译:发现多靶点药物作为广谱抗病毒药物和囊性纤维化校正剂,用于相关肺部疾病的跨膜电导调节剂

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Enteroviruses (EVs) are among the most frequent infectious agents in humans worldwide and represent the leading cause of upper respiratory tract infections. No drugs for the treatment of EV infections are currently available. Recent studies have also linked EV infection with pulmonary exacerbations, especially in cystic fibrosis (CF) patients, and the importance of this link is probably underestimated. The aim of this work was to develop a new class of multitarget agents active both as broad-spectrum antivirals and as correctors of the F508del-cystic fibrosis transmembrane conductance regulator (CFTR) folding defect responsible for >90 of CF cases. We report herein the discovery of the first small molecules able to simultaneously act as correctors of the F508del-CFTR folding defect and as broad-spectrum antivirals against a panel of EVs representative of all major species.
机译:肠道病毒 (EV) 是全球人类中最常见的传染源之一,是上呼吸道感染的主要原因。目前尚无治疗 EV 感染的药物。最近的研究也将 EV 感染与肺部加重联系起来,尤其是在囊性纤维化 (CF) 患者中,这种联系的重要性可能被低估了。这项工作的目的是开发一类新的多靶点药物,既可以作为广谱抗病毒药物,也可以作为 F508del 囊性纤维化跨膜电导调节因子 (CFTR) 折叠缺陷的校正剂,该缺陷导致 >90% 的 CF 病例。我们在此报告了第一批能够同时作为 F508del-CFTR 折叠缺陷的校正剂和针对代表所有主要物种的一组 EV 的广谱抗病毒剂的小分子的发现。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号